AWM Investment Company Inc. trimmed its holdings in OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 79.9% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 215,421 shares of the company's stock after selling 856,411 shares during the period. AWM Investment Company Inc. owned 1.17% of OptimizeRx worth $1,047,000 at the end of the most recent reporting period.
Several other hedge funds have also made changes to their positions in the business. Barclays PLC raised its stake in OptimizeRx by 358.5% during the 3rd quarter. Barclays PLC now owns 26,934 shares of the company's stock valued at $208,000 after acquiring an additional 21,060 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of OptimizeRx during the fourth quarter worth $51,000. Greenwood Capital Associates LLC grew its position in OptimizeRx by 31.5% in the 4th quarter. Greenwood Capital Associates LLC now owns 88,596 shares of the company's stock valued at $431,000 after buying an additional 21,240 shares during the last quarter. AMH Equity Ltd grew its position in OptimizeRx by 25.0% in the 4th quarter. AMH Equity Ltd now owns 125,000 shares of the company's stock valued at $608,000 after buying an additional 25,000 shares during the last quarter. Finally, SBI Securities Co. Ltd. purchased a new position in OptimizeRx during the 4th quarter worth $25,000. Institutional investors and hedge funds own 76.47% of the company's stock.
Wall Street Analysts Forecast Growth
OPRX has been the topic of a number of analyst reports. JMP Securities lifted their price objective on OptimizeRx from $11.00 to $14.00 and gave the company a "market outperform" rating in a report on Tuesday, May 13th. Citigroup reaffirmed an "outperform" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Stifel Nicolaus boosted their target price on shares of OptimizeRx from $8.00 to $12.50 and gave the company a "buy" rating in a report on Tuesday, May 13th. Wall Street Zen upgraded OptimizeRx from a "hold" rating to a "buy" rating in a report on Thursday. Finally, B. Riley reissued a "buy" rating on shares of OptimizeRx in a report on Tuesday, May 13th. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $10.38.
Check Out Our Latest Research Report on OPRX
OptimizeRx Stock Performance
Shares of OPRX traded down $0.44 during midday trading on Monday, hitting $11.65. 250,250 shares of the stock traded hands, compared to its average volume of 279,372. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23. OptimizeRx Co. has a 1-year low of $3.78 and a 1-year high of $13.00. The business's 50 day moving average price is $9.16 and its two-hundred day moving average price is $6.71. The firm has a market capitalization of $215.47 million, a PE ratio of -8.76 and a beta of 1.28.
OptimizeRx (NASDAQ:OPRX - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of ($0.11) by $0.19. The firm had revenue of $21.93 million during the quarter, compared to analysts' expectations of $18.69 million. OptimizeRx had a negative net margin of 27.41% and a negative return on equity of 4.92%. Equities research analysts predict that OptimizeRx Co. will post -0.33 EPS for the current fiscal year.
Insider Buying and Selling at OptimizeRx
In other OptimizeRx news, Director James Paul Lang purchased 321,408 shares of the firm's stock in a transaction dated Friday, March 14th. The stock was bought at an average price of $7.60 per share, with a total value of $2,442,700.80. Following the completion of the purchase, the director now owns 389,452 shares in the company, valued at $2,959,835.20. This trade represents a 472.35% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 5.60% of the stock is owned by company insiders.
About OptimizeRx
(
Free Report)
OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.
Read More
Before you consider OptimizeRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OptimizeRx wasn't on the list.
While OptimizeRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
